NDAORALTABLET
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
19
Mechanism of Action
Bruton's Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Started Oct 2025
60 enrolled
Immune Thrombocytopenia
Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan
Started Oct 2025
4 enrolled
Immune Thrombocytopenia
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Started Sep 2025
124 enrolled
Immunoglobulin G4 Related Disease
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
Started Sep 2025
30 enrolled
Graves' Disease
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
Started Aug 2025
90 enrolled
Autoimmune Haemolytic Anaemia
Loss of Exclusivity
LOE Date
Feb 20, 2041
182 months away
Patent Expiry
Feb 20, 2041
Exclusivity Expiry
Aug 29, 2030